Navigation Links
Cylene Initiates Phase I Trial in Multiple Myeloma With CX-4945 Inhibitor of CK2 and Closes Accompanying Financing
Date:9/24/2010

SAN DIEGO, Sept. 24 /PRNewswire/ -- Cylene Pharmaceuticals, Inc. announced today the initiation of a Phase I clinical trial of their first-in-class, oral CK2 inhibitor CX-4945 in patients with multiple myeloma. Cylene also announced the simultaneous closing of a $12 million financing with participation from existing investors including Sanderling Ventures, HBM BioVentures (Cayman) Ltd., Novartis BioVenture Fund, BioVentures Investors, Lilly Ventures, Mitsui & Co. and Morningside Venture Investments Ltd. Proceeds from the financing will be used to expand the human clinical trials program for CX-4945, including the Phase I trial in patients with multiple myeloma and a series of randomized Phase II trials.

The multi-center Phase I study with CX-4945 will be conducted in patients with relapsed or refractory multiple myeloma. The primary objectives of the study are to determine the safety, tolerance and pharmacokinetic (PK) properties of CX-4945 in multiple myeloma patients and to select the appropriate dose for Phase II trials. Secondary objectives are to investigate the pharmacodynamic (PD) activity of CX-4945 using mechanism and tumor-related PD biomarkers that have been validated in both preclinical and clinical studies. In preclinical studies with multiple myeloma cell lines, CX-4945 inhibited critical CK2-mediated events including key signaling pathways and mediators (PI3K/Akt, NFkB, IL-6) that are known to drive the proliferation of multiple myeloma. These findings, coupled with the need for new agents that target molecular pathways shared by all subtypes of multiple myeloma, highlight CX-4945 as a promising therapeutic agent for multiple myeloma.

A separate Phase I clinical trial in patients with solid tumors evaluating CX-4945 as an orally administered single agent has already established favorable pharmacokinetic and safety profiles. Measurement of mechanism and tumor-related biomarkers in patients established that CX-4945 hits the CK2 targ
'/>"/>

SOURCE Cylene Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cylene Pharmaceuticals Initiates Phase II Clinical Trial of Quarfloxin (CX-3543) in Patients With Carcinoid/Neuroendocrine Tumors
2. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
3. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
4. Emerging Growth Equities, Ltd. Initiates Coverage of CombiMatrix Corporation with a BUY Rating and an $18.00 Price Target
5. NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
6. CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases
7. Masimo Initiates Limited Release of First-Ever Noninvasive and Continuous Hemoglobin Monitors
8. Sinovac Initiates Clinical Trials for Inactivated Hepatitis A Vaccine in Ukraine
9. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
10. SenesTech, Inc. Initiates Research Field Trials for ContraPest(R) in Indonesia
11. Portola Pharmaceuticals Initiates Phase II Trial of Betrixaban, its Novel Oral Factor Xa Inhibitor for Stroke Prevention in Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... 23, 2014 Shimadzu Scientific Instruments ... acid analysis system developed jointly with Ajinomoto Co. ... can analyze 38 amino acids in nine minutes, ... achieves high-speed analysis utilizing a fast application-specific column ... accurate analytical results even under conditions with difficult ...
(Date:7/23/2014)... AVIV, Israel , July 23, 2014 /PRNewswire/ ... ., a portfolio company of Trendlines Agtech ... one of Israel,s leading ... http://photos.prnewswire.com/prnh/20140121/666259-a) , Valentis,s technology combines nanocrystalline ... plant pulp waste, with additional nanoparticles to produce ...
(Date:7/23/2014)...  GrowBLOX Sciences, Inc. (OTCQB: GBLX), a medical cannabis research ... two medical marijuana dispensary locations in Las Vegas, ... Clark County, Nevada dispensary for which ... announced.  GrowBLOX Sciences, CEO Craig Ellins ... for dispensaries in the City of Las Vegas ...
(Date:7/23/2014)... a2z Inc. announces that AACC will ... Pathfinder, in its 2014 Annual Meeting & Clinical ... planned for July 29-31, 2014 in Chicago, IL at ... connect with global leaders in clinical chemistry, molecular diagnostics, ... of breaking science in laboratory medicine. , ChirpE Photo ...
Breaking Biology Technology:Shimadzu's New UF-Amino Station Provides High-Speed, Multi-Component Analysis of Amino Acids in Food & Beverage and Pharmaceutical Testing 2Valentis Nanotech Signs MOU to Integrate Technology in Thermoplastics Production 2GrowBLOX Sciences, Inc. Files for Two Additional Medical Marijuana Dispensaries in Las Vegas 2GrowBLOX Sciences, Inc. Files for Two Additional Medical Marijuana Dispensaries in Las Vegas 3AACC Enhances Attendee Experience at Its 2014 Annual Meeting & Clinical Lab Expo with a2z-Powered ChirpE Photo Booth and Mobile App 2AACC Enhances Attendee Experience at Its 2014 Annual Meeting & Clinical Lab Expo with a2z-Powered ChirpE Photo Booth and Mobile App 3
... 2011 Omega Protein Corporation (NYSE symbol: OME), a ... Omega-3 fish oil and specialty fish meal products, today ... a strategic advisor in connection with its omega-3 fish ... Lipid Technologies is an analytical services and biotechnology ...
... Mass. and SYDNEY, Oct. 21, 2011 HeartWare International, Inc. ... its financial results for the three and nine months ended ... on Friday, October 28, 2011 (being 11:00 pm Australian Eastern ... release the financial results prior to the conference call. ...
... Today, Congressman Eric Cantor (VA-07) and Tonya Mallory, co-founder, ... Inc.), a CAP accredited leader in health management, ... and economic growth with local business leaders at the ... (Photo: http://photos.prnewswire.com/prnh/20111020/PH91012 ) "We all ...
Cached Biology Technology:Omega Protein Announces Retention of Lipid Technologies, LLC 2HeartWare Schedules Third Quarter Conference Call and Webcast 2Congressman Eric Cantor and Health Diagnostic Laboratory, Inc. Discuss Job Growth at Virginia BioTechnology Research Park 2Congressman Eric Cantor and Health Diagnostic Laboratory, Inc. Discuss Job Growth at Virginia BioTechnology Research Park 3
(Date:7/23/2014)... its grip is affecting more than the color of people,s ... a heat-loving amoeba commonly found in warm freshwater bodies, such ... made warmer than usual this year. , A 9-year-old Kansas ... after swimming in several area lakes. The amoeba enters the ... the brain. Nose plugs can lower the odds of this ...
(Date:7/23/2014)... blow fly Chrysomya megacephala is commonly found ... to determine the time of death, referred to as ... form of C. megacephala from Tamil Nadu ... features and molecular characterization through generation of DNA barcoding. ... the open access Biodiversity Data Journal . , ...
(Date:7/23/2014)... around the world by 2050, according to one of ... Change (IPCC), may be advantageous to the physiology and ... of forage plants such as Stylosanthes capitata Vogel ... countries such as Brazil., The conclusion is from a ... Biology at the Ribeiro Preto Faculty of Philosophy, Sciences ...
Breaking Biology News(10 mins):Diseases of another kind 2Dead body feeding larvae useful in forensic investigations 2An increase in temperature by 2050 may be advantageous to the growth of forage plants 2An increase in temperature by 2050 may be advantageous to the growth of forage plants 3An increase in temperature by 2050 may be advantageous to the growth of forage plants 4
... Dr. Sydney Finegold, research is like reading a really good mystery ... one can see the results in one's own patients," he said. ... , With a grant from the Department of Defense, Finegold has ... that affects civilians as well as injured service members: wound bacteria. ...
... ?the world's last great wilderness ?from invasive non-native species ... in Edinburgh. , Scientists and policy makers at the ... Conference Centre on Friday 23 June, agreed new measures ... introduced into both marine and terrestrial ecosystems in Antarctica. ...
... atmospheric ozone -- which protects Earth from the sun's ... the most important regions of the stratosphere above the ... new study shows. , Researchers attribute the improvement to ... the global Montreal Protocol treaty and its amendments and ...
Cached Biology News:Technique speeds up detecting, treating wound bacteria 2Technique speeds up detecting, treating wound bacteria 3Antarctic Treaty Meeting moves to protect frozen continent from non-native species 2Atmospheric ozone recovering in mid-latitudes, report shows 2Atmospheric ozone recovering in mid-latitudes, report shows 3Atmospheric ozone recovering in mid-latitudes, report shows 4
... A full-featured high-performance ICP-MS system designed for ... interface, Omega II off-axis ion lens, true ... 7500a can handle the widest range of ... the 7500a now includes as standard Agilents ...
... that it uses a deep-UV deuterium bulb, which ... with a shutter (controlled via a TTL signal ... DH-2000 Deuterium Tungsten Halogen Light Source combines ... light sources in a single optical path. The ...
One controller two vessel system suitable for early stage of fermentation, and small scale, Application : cultivation of microorganisms and human or animal cells...
... space and organize gloves, safety glasses, ... are the perfect benchtop storage bins ... processing and manufacturing. Clear static-dissipative PVC ... they attract. Many other sizes and ...
Biology Products: